Trauma- and stress-related disorders are encountered by most psychiatrists regularly. However, with the notable exception of post-traumatic stress disorder (PTSD), they have received little academic attention. Other conditions considered more severe, such as depressive disorders, attract more interest and more research funding. Casey & Strain's book provides a much-needed guide to these debilitating but neglected conditions. The authors question whether the common stressor-related conditions of adjustment disorder (AD) and acute stress disorder (ASD) are mild sub-threshold conditions or threshold psychopathology.

The charge of ‘the medicalisation of ordinary suffering’ is one frequently levelled at psychiatry – a criticism based on the popular misconception that psychiatry views unhappiness, and even life itself, as pathology rather than as a core aspect of the human condition. Some academics have argued against the vagueness of the diagnosis and diagnostic criteria of AD and ASD, although this very factor makes them useful in clinical practice. Psychiatrists need the categories of ASD and AD to acknowledge distress with functional impairment which is in excess of cultural norms, without the need for a diagnosis of a depressive illness or anxiety disorder and its attendant ramifications for prognosis and treatment.

Trauma- and Stressor-Related Disorders provides a succinct, thorough overview of these conditions, without eschewing the controversies. The opening chapter sets the tone with the oft-debated topic of the borderline between normal and pathological responses to stress. Four chapters are dedicated to the much neglected diagnosis of AD, then one chapter each for ASD, PTSD, dissociation and bereavement. The final three chapters add further considerations: resilience in the genesis of ASD, PTSD, dissociation and bereavement. The central role of the art of psychiatry: clinical judgement. The controversies surrounding these diagnoses head-on, and stress the central role of the art of psychiatry: clinical judgement. The importance of clinical judgement, the skill of combining it with the diagnostic criteria and a nuanced understanding of the context and personalities in which disorders arise, is a strong theme in this book.

It has always been interesting to treat people with bipolar disorder, because of the challenges of their varied presentations and their inherent potential for originality. The advent of lithium and antipsychotics opened the way for making real differences in their lives, but progress was slow in understanding the indications and limitations of treatments. Inspired clinician-researchers such as Jules Angst and Frederick Goodwin paved the way for a systematic approach to elucidating the condition. Charles Bowden's randomised controlled studies of valproate in the 1990s stimulated investment from the pharmaceutical industry that has enabled a firm evidence base to be developed and the introduction of a wide range of agents, particularly new antipsychotics and anticonvulsants with mood-modifying properties.

The challenge now for clinicians is to make sense of the new evidence and find ways to apply it for individual patients. The 2016 Guidelines of the British Association for Psychopharmacology provide a well written and balanced summary from a UK perspective. However, it is also instructive to recognise the perspective from the USA, where clinicians have different priorities and are very alert to new developments. Differences and indeed controversies exist – about the efficacy of antidepressants, for example, and which agents deserve the epithet ‘mood stabiliser’.

The editor and main author of this book, Terence Ketter from Stanford University, is known for his clear understanding of the relevance of clinical trial findings. With experts from specialist areas he presents eight chapters on topics ranging across the life cycle, and across the different phases of the illness. He analyses individual trials for what they tell us about the efficacy and side-effects of a particular drug, and how large a clinical effect it may yield, using number-needed-to-treat analyses and a five-tier hierarchy of evidence.

The chapter on mania endorses the combination of intramuscular haloperidol with lorazepam for severe agitation, in contrast to new National Institute for Health and Care Excellence guidelines (NG10, 2015). Ironically, although valproate does not have Food and Drug Association (FDA) approval for prevention, the combination of an antipsychotic (in the case of risperidone, quetiapine, aripiprazole and ziprasidone) with valproate or lithium does. For prevention in paediatric bipolar disorder the only FDA-approved medicines are lithium and aripiprazole. Amongst lower-tier options discussed are lurasidone and cariprazine, along with ketamine, modafinil, ramelteon and nutraceuticals such as omega-3 fatty acids. There is also a long chapter on pharmacology side-effects and interactions, a subject on which US clinicians are most expert.

Anne Doherty University College Hospital Psychiatric Unit, Newcastle Road, Galway, Ireland. Email: c/o bjpsych@rcpsych.ac.uk
doi: 10.1192/bjp.bp.116.187591